Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986340 as Monotherapy and Combination Therapy in Advanced Solid Tumors
NCT04895709Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- May 2021
- Primary completion
- Aug 2031
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of imzokitug in Cervical Cancer (CC), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma (RCC), sponsored by Bristol Myers Squibb. Started May 2021; status: recruiting.
02
Drugs
imzokitug
03
Conditions
Cervical Cancer (CC)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04895709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04895709.